Stephen Carey Sells 7,312 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 7,312 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $75.50, for a total transaction of $552,056.00. Following the transaction, the chief financial officer directly owned 185,543 shares in the company, valued at approximately $14,008,496.50. The trade was a 3.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

ANI Pharmaceuticals Price Performance

Shares of ANIP traded down $0.93 during mid-day trading on Thursday, hitting $75.60. 314,015 shares of the company were exchanged, compared to its average volume of 458,954. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of 22.50 and a beta of 0.52. ANI Pharmaceuticals, Inc. has a 1-year low of $56.71 and a 1-year high of $99.50. The company has a 50 day moving average of $79.92 and a 200-day moving average of $86.11. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.19 and a current ratio of 2.71.

Analysts Set New Price Targets

A number of research analysts have weighed in on ANIP shares. Guggenheim raised their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Barclays assumed coverage on shares of ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $103.43.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANIP. Arrowstreet Capital Limited Partnership purchased a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth $32,992,000. Balyasny Asset Management L.P. lifted its position in ANI Pharmaceuticals by 2,785.7% in the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after buying an additional 276,233 shares during the last quarter. Divisadero Street Capital Management LP purchased a new position in ANI Pharmaceuticals during the third quarter worth about $21,454,000. Rubric Capital Management LP boosted its stake in ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after buying an additional 200,998 shares during the period. Finally, UBS Group AG increased its position in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after acquiring an additional 185,172 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Key Headlines Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Analyst support remains strong — Guggenheim has reiterated/maintained a buy stance and has previously raised its target (recent coverage keeps favorable analyst attention, supporting longer-term demand). Guggenheim Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP)
• Positive Sentiment: Reported insider buy: a Benzinga item flags an SVP & CFO purchase of roughly $1.7M of ANIP stock — insider buying can be a positive signal about management’s view of valuation. SVP & CFO At ANI Pharmaceuticals Buys $1.72M of Stock
• Neutral Sentiment: Short interest readings in recent reports show 0 shares (figures include NaN/inconsistent values and days-to-cover of 0.0), suggesting reporting oddities rather than a meaningful short-squeeze risk at present.
• Negative Sentiment: Material insider selling by the CFO — Stephen P. Carey sold 7,312 shares at an average of $75.50 (disclosed via SEC filing). While the CFO still holds a large stake, the sale reduces insider position and can pressure sentiment. CFO Form 4 (SEC)
• Negative Sentiment: Other insider sales: SVP Ori Gutwerg sold 2,060 shares at ~$76.50 (SEC filing) and insider Christopher Mutz sold 417 shares at $74 (plus a prior sale of 5,323 shares on Feb 20). Multiple near-term insider sales can weigh on near-term sentiment. Ori Gutwerg Form 4 (SEC) InsiderTrades: Christopher Mutz sale

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.